Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. 

In this episode Tim chats to Steven Yatomi-Clarke, CEO of Prescient Therapeutics (ASX:PTX).

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Prescient’s PTX-100 has been granted FDA’s Orphan Drug Designation for all T-cell lymphomas. The company now hopes to accelerate a bid for US FDA study approval for targeted therapy PTX-100.

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1).

To hear Tim and Steve discuss all this and more, click below!

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!